Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 9Terminated 2Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Lymphoma, Non-Hodgkin 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × chiauranib × Clear all
NCT05336721 2025-03-24

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Chipscreen Biosciences, Ltd.

Phase 2 Terminated
9 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1 Terminated
5 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡